PharmaMar gets first $25 million as first milestone payment from Jazz Pharma

7 March 2022

Spanish drugmaker PharmaMar’s (MC: PHM) shares closed down 7.5% at 54.90 euros on Friday, despite announcing the receipt of payment of $25 million (22 million euros) from its US partner, Jazz Pharmaceuticals (Nasdaq: JAZZ), after reaching the first commercial milestone, set out in its license agreement in relation to 2021 sales.

After a successful launch of Zepzelca (lurbinectedin) in the USA by Jazz Pharmaceuticals, lurbinectedin is established as the treatment of choice in second-line small cell lung cancer (SCLC). The sales achieved in 2021 have resulted in the first commercial milestone payment.

Lurbinectedin received accelerated approval for the second-line treatment of SCLC in June 2020 in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK